Some clinicians have recommended synthetic lethality with poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors for patients with a subtype of kidney cancer, including Von Hippel-Lindau (VHL)-altered clear cell renal cell carcinoma (ccRCC), fumarate hydratase (FH)- and succinate dehydrogenase (SDH)-deficient RCC, and renal medullary carcinoma (RMC), which are affected by genomic instability. ...
Advanced Renal Cell Carcinoma
Advertisement
Latest News
Bempegaldesleukin can initialize effector CD8+ T cells and natural killer cells in the tumor microenvironment.
Dr. Tawagi considers how "favorable" and "very favorable" risk alters her approach to patient management for aRCC.
Dr. Zhang highlights the results of a phase 2 trial for sequential treatment of cabozantinib in advanced RCC.
The discussion focused on advanced and metastatic stages of RCC, shedding light on current practices in clinics.
The combination of SRS with IO significantly increases the OS in RCCBM compared with IO, WBRT, or WBRT plus IO.
The KEYNOTE-426 study explored pembrolizumab and axitinib vs sunitinib in advanced RCC using genetic biomarkers.
Advertisement
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
![PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC](https://mumcdnstorage.blob.core.windows.net/guonc/2024/06/122-GUOnc_YouTube_Sartor_1280x720.jpg)
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
Advertisement
Section Editor
Katy Beckermann, MD, PhDGenitourinary Medical Oncologist | Vanderbilt-Ingram Cancer Center
Advertisement
Get the latest RCC research straight to your inbox.
